Jens Geginat
Overview
Explore the profile of Jens Geginat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
6553
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Esposito E, Marra G, Catalano R, Maioli S, Nozza E, Barbieri A, et al.
Int J Cancer
. 2024 Nov;
156(6):1256-1271.
PMID: 39528354
Filamin A (FLNA) is poorly expressed in adrenocortical carcinomas (ACC) compared to adenomas (ACA). Its presence is associated to a less aggressive tumour behaviour, potentially due to its role in...
2.
Harari S, Elia D, Caminati A, Geginat J, Luisi F, Pelosi G, et al.
Lancet Respir Med
. 2024 Nov;
12(12):967-974.
PMID: 39489895
Background: Lymphangioleiomyomatosis is an ultra-rare disease mainly affecting women of childbearing age. The MILES trial showed the efficacy of sirolimus, an mTOR inhibitor, in stabilising lung function in patients with...
3.
Kumar S, Basto A, Ribeiro F, Almeida S, Campos P, Peres C, et al.
Cell Discov
. 2024 Jun;
10(1):64.
PMID: 38834551
Effective antibody responses are essential to generate protective humoral immunity. Different inflammatory signals polarize T cells towards appropriate effector phenotypes during an infection or immunization. Th1 and Th2 cells have...
4.
Muller I, Maioli S, Armenti M, Porcaro L, Curro N, Iofrida E, et al.
Eur Thyroid J
. 2024 Mar;
13(2).
PMID: 38471303
Introduction: Secondary thyroid autoimmunity, especially Graves' disease (GD), frequently develops in patients with multiple sclerosis (MS) following alemtuzumab treatment (ALTZ; anti-CD52). Thyroid eye disease (TED) can also develop, and rituximab...
5.
Galeota E, Bevilacqua V, Gobbini A, Gruarin P, Bombaci M, Pesce E, et al.
Clin Immunol
. 2024 Feb;
261:110164.
PMID: 38417765
Multiple vaccines have been approved to control COVID-19 pandemic, with Pfizer/BioNTech (BNT162b2) being widely used. We conducted a longitudinal analysis of the immune response elicited after three doses of the...
6.
Pulvirenti N, Silvetri Y, Clemente F, Bosotti R, Carelli E, Moschetti G, et al.
Eur J Immunol
. 2024 Feb;
54(4):e2350675.
PMID: 38396108
Human CD4EOMES T cells are heterogeneous and contain Th1-cells, Tr1-cells, and CD4CTL. Tr1- cells and non-classical EOMES Th1-cells displayed, respectively, anti- and pro-inflammatory cytokine profiles, but both expressed granzyme-K, produced...
7.
Rossi R, Elia D, Torre O, Cassandro R, Caminati A, Bulgheroni E, et al.
Am J Respir Cell Mol Biol
. 2024 Feb;
70(2):146-148.
PMID: 38299793
No abstract available.
8.
Paroni M, Leccese G, Ranzani V, Moschetti G, Chiara M, Perillo F, et al.
J Crohns Colitis
. 2023 Jul;
17(12):1988-2001.
PMID: 37462681
IFNγ-producing ex-Th17 cells ['Th1/17'] were shown to play a key pathogenic role in experimental colitis and are abundant in the intestine. Here, we identified and characterised a novel, potentially colitogenic...
9.
Silvestri Y, Clemente F, Moschetti G, Maioli S, Carelli E, Espadas de Arias A, et al.
Clin Immunol
. 2023 Jul;
254:109684.
PMID: 37451415
Background: SARS-CoV-2 infections have been associated with the onset of thyroid disorders like classic subacute thyroiditis (SAT) or atypical SAT upon severe COVID disease (COV-A-SAT). Little is known about thyroid...
10.
Geginat J, Vasco C, Gruarin P, Bonnal R, Rossetti G, Silvestri Y, et al.
Eur J Immunol
. 2023 Jan;
53(5):e2149775.
PMID: 36653901
Type 1 regulatory (Tr1) T cells are currently defined all T cells with regulatory functions that lack FOXP3 expression and produce IL-10. Tr1 cells are heterogeneous, and the different reported...